Dossier assessment
Iptacopan (complement 3 glomerulopathy) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Iptacopan (complement 3 glomerulopathy) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Iptacopan (complement 3 glomerulopathy) – Benefit assessment according to §35a Social Code Book V
Drug assessment at a glance
-
Drug assessment at a glance
Iptacopan (complement 3 glomerulopathy) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with complement 3 glomerulopathy
- Iptacopan as add-on therapy to mycophenolate mofetil and corticosteroids: added benefit not proven (based on the results of the relevant study)
- Iptacopan monotherapy: added benefit not proven (no relevant study)
Project details
- Project no.
- A25-157
- Commission
- Commission awarded on 15.12.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Kidneys and urinary system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-157
Connected Projects
-
Dossier assessment
Iptacopan (complement 3 glomerulopathy) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Iptacopan (paroxysmal nocturnal haemoglobinuria with haemolytic anaemia) – Assessment according to §35a SGB V (1), Sentence 11
Status: Commission completed
-
Dossier assessment
Iptacopan (paroxysmal nocturnal haemoglobinuria) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed